Harvard Bioscience Unveils Innovations at Safety Pharmacology Event

Harvard Bioscience Showcases Innovations at Safety Pharmacology Society

Harvard Bioscience, Inc. (NASDAQ: HBIO) is set to unveil its latest advancements at the Safety Pharmacology Society Annual Meeting. This event will take place over several days in San Diego, where cutting-edge products and technologies will take center stage in the life sciences community.

Integration of DSI™ Ponemah™ Data Management Platform

The Ponemah™ platform is an industry-leading tool designed for managing data from various preclinical studies. It meets rigorous GLP standards and integrates seamlessly with DSI's SoHo™ implantable telemetry and VivaMARS™ behavior monitoring systems. This innovative solution facilitates the efficient collection and processing of extensive in-vivo data, bridging preclinical studies with new in-vitro testing methods.

The Role of Machine Learning

Ponemah also lays the groundwork for future integration of advanced machine learning algorithms. This enhancement aims to revolutionize the analysis of large, complex data sets generated during research.

Advancements in SoHo™ Implantable Telemetry

The SoHo telemetry system, recently launched, is gaining popularity among leading researchers in the preclinical field. Its compact design allows for the examination of various small animal models, fostering natural shared housing conditions. These improvements, alongside new power management features, extend the duration of longitudinal studies.

Optimizing Efficiency

With the addition of Ponemah platform compatibility, the telemetry system streamlines the process of data collection and reporting. This integrated approach reduces operational costs and significantly enhances testing throughput.

Introducing the VivaMARS™ Activity Monitoring System

The VivaMARS system is another highlight at the meeting, providing a robust platform for high-throughput behavioral assessments in neuropharmacology safety and toxicology studies. When paired with Ponemah, VivaMARS forms a comprehensive, compliant solution that caters to the needs of CROs and pharmaceutical companies.

Showcasing Results

At the Safety Pharmacology event, early data showcasing the VivaMARS system will be presented. This system marks a significant innovation in automated behavioral testing, ensuring it is ready for use at various stages of research.

Mesh MEA™ Organoid Platform Highlights

The company will also spotlight its Mesh MEA™ platform, which enhances organoid research. This platform allows researchers to gather precise electrophysiological data from living organoids in real-time. This development is set to reshape applications in safety pharmacology and toxicology.

Current Evaluations and Future Prospects

Currently, the Mesh MEA platform is being tested across specialized research sites, with full production anticipated soon. The platform's ability to efficiently screen in-vitro samples opens new avenues for more accurate assessment with fewer animal models.

Commitment to New Therapies

Jim Green, Chairman and CEO of Harvard Bioscience, expressed excitement about the company's success at the SPS Conference, particularly with the first production sales of the SoHo implants. Harvard Bioscience is collaborating with leading research organizations to further advance its systems and ensure their effective integration into current practices.

Meet Harvard Bioscience at the Annual Meeting

The company will exhibit its range of solutions at booth 501 during the Safety Pharmacology Society Annual Meeting, providing hands-on demonstrations and discussions with attendees from various disciplines within the industry.

About Harvard Bioscience

Harvard Bioscience, Inc. is dedicated to facilitating breakthroughs in life sciences through its innovative products and technologies. Catering to a diverse clientele, from academic institutions to top pharmaceutical companies, Harvard Bioscience oversees operations globally, including in North America, Europe, and China.

Frequently Asked Questions

What is the focus of Harvard Bioscience's presentation at the SPS Annual Meeting?

The company will showcase its latest advancements in telemetry systems, data management platforms, and organoid research applications.

How does the Ponemah platform integrate with other systems?

Ponemah integrates with DSI's SoHo telemetry and VivaMARS systems, providing a comprehensive data management solution.

What are the key features of the SoHo telemetry system?

The SoHo telemetry system features a compact design and enhanced power management for extended studies.

What innovations does the VivaMARS system offer?

VivaMARS enables high-throughput behavioral testing and integrates well with the Ponemah platform for data analysis.

Who can benefit from Harvard Bioscience products?

Researchers, pharmaceutical companies, and academic institutions can all leverage the innovative solutions offered by Harvard Bioscience for their studies.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.